Document is current
Any future updates will be listed below
-
Authors
Zhang, Kehua
Na, Tao
Jia, Chuncui
Yuan, Xianghe
Guo, Meichen
Yang, Xu
Li, Min
Jia, Wenwen
Bai, Zhihui
Lu, Jizhen
Liu, Zhongmin
Meng, Shufang
-
Funding
Funding for this research was provided by:
Natural Key Research and Development Program (2021YFA1101601)
Natural Key Research and Development Program (2021YFA1101601)
Natural Key Research and Development Program (2021YFA1101601)
Natural Key Research and Development Program (2021YFA1101601)
Natural Key Research and Development Program (2021YFA1101601)
Natural Key Research and Development Program (2021YFA1101601)
Natural Key Research and Development Program (2021YFA1101601)
State Key Laboratory of Drug Regulatory Science Project (2023SKLDRS0122)
State Key Laboratory of Drug Regulatory Science Project (2023SKLDRS0122)
State Key Laboratory of Drug Regulatory Science Project (2023SKLDRS0122)
State Key Laboratory of Drug Regulatory Science Project (2023SKLDRS0122)
State Key Laboratory of Drug Regulatory Science Project (2023SKLDRS0122)
State Key Laboratory of Drug Regulatory Science Project (2023SKLDRS0122)
State Key Laboratory of Drug Regulatory Science Project (2023SKLDRS0122)
State Key Laboratory of Drug Regulatory Science Project (2023SKLDRS0122)
- License Information
-
More Information
Article History
Received: 3 September 2025
Accepted: 11 March 2026
First Online: 25 March 2026
Declarations
:
: Preparation and banking of human iPSC lines were approved by Human Cell Clinical Research Ethics Committee of Shanghai East Hospital, Tongji University. The approved project title is “Preparation and Banking of Clinical-grade Human HLA High-matched iPS Cells” (Approval number: [2018] Tilinshen No. (002). Date of approval: August 22, 2018.).
: The authors declare no competing interests.
: The authors declare that they have not used AI-generated work in this manuscript.
